| (Values in U.S. Thousands) | Aug, 2026 | Aug, 2026 | Aug, 2026 | Aug, 2026 | Aug, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Oxurion NV (TBGNF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ThromboGenics NV was incorporated on May 30, 2006. The Company is an integrated biopharmaceutical company engaged in developing and commercializing new pharmacologic treatments that address unmet clinical needs in ophthalmology and oncology. Its product, JETREA, has been approved by the U.S. FDA for the treatment of symptomatic VMA/AMT. In Europe, it has been approved for the treatment of vitreomacular traction, or VMT, including when associated with macular hole of diameter less than or equal to 400 microns. Its marketing activities are extended to the general ophthalmology community and to patient associations.